- Bausch + Lomb, a leading global eye health business of Bausch Health (NYSE:BHC) announces that VYZULTA, which is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension, now has expanded public drug program reimbursement in the provinces of Alberta, Saskatchewan, Manitoba, New Brunswick, Nova Scotia, Newfoundland and Labrador and as part of the federal Non-Insured Health Benefits.
- These provinces join Ontario, which made VYZULTA available to patients in December 2019.
- Bausch Health's VYZULTA OK'd in Ukraine
- Source: Press Release